Dyne Therapeutics is advancing z-rostudirsen toward approval for DMD after data showed increased dystrophin and early functional trends.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results